April 04, 2025

First FDA-Approved IgG4-RD Treatment

A humanized monoclonal antibody that targets CD19+ B cells becomes the first and only FDA-approved treatment for immunoglobulin G4–related disease, reducing flare risk and glucocorticoid use in clinical trials.

Conexiant

April 04, 2025

Gram-Negative Infection: 7 vs 14 Days of Antibiotics

Researchers found that seven days of antibiotics is likely noninferior to 14 days for Gram-negative bloodstream infections, supporting shorter treatment durations.

Conexiant

April 03, 2025

New Option for IgA Nephropathy Management

The FDA has granted accelerated approval to Vanrafia (atrasentan) for reducing proteinuria in adults with primary immunoglobulin A nephropathy who are at risk of rapid disease progression.

Conexiant

April 01, 2025

FDA Monthly Round-Up: Key March Updates

March’s FDA approvals feature new biosimilars, first-in-class therapies, expanded indications, and diagnostic innovations across allergy, cardiology, gastroenterology, infectious diseases, and more.

Conexiant

March 31, 2025

Tariff Threat: Drugs Could Cost U.S. $750M More

New research reveals 25% tariffs on Canadian pharmaceuticals would impact critical medications, strain supply chains, and potentially increase costs—with 28 drugs having no alternative suppliers.

Conexiant

March 25, 2025

New Oral Antibiotic Targets Uncomplicated UTIs

FDA approves gepotidacin, a first-in-class oral antibiotic, for treating uncomplicated urinary tract infections in females aged 12 and older, based on phase III trial results.

Conexiant

March 25, 2025

Researchers Question Routine Urodynamic Testing

The researchers found that invasive urodynamic testing did not improve outcomes or cost-effectiveness in women with refractory overactive bladder symptoms.

Conexiant

March 21, 2025

Vutrisiran Receives FDA Nod for ATTR Amyloidosis With Cardiomyopathy

The FDA approves vutrisiran (Amvuttra) as the first RNAi therapeutic to reduce cardiovascular events and mortality in adults with transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.

Conexiant

March 19, 2025

Study: Sex Differences in Physician Suicide

Researchers found that female physicians had a significantly higher suicide risk than female nonphysicians.

Conexiant